Literature DB >> 17522439

Signal transduction cascades associated with oxidative stress in Alzheimer's disease.

Robert B Petersen1, Akihiko Nunomura, Hyoung-gon Lee, Gemma Casadesus, George Perry, Mark A Smith, Xiongwei Zhu.   

Abstract

It has now been established through multiple lines of evidence that oxidative stress is an early event in Alzheimer's disease, occurring prior to the canonical cytopathology. Thus, oxidative stress likely plays a key pathogenic role in the disease and is clearly involved in the cell loss and other neuropathology associated with Alzheimer's disease as demonstrated by the large number of metabolic signs of oxidative stress and by markers of oxidative damage. One puzzling observation, however, is that oxidative damage decreases with disease progression, such that levels of markers of rapidly formed oxidative damage, which are initially elevated, decrease as the disease progresses to advanced Alzheimer's disease. This finding indicates that reactive oxygen species not only cause damage to cellular structures but also provoke cellular responses, such as the compensatory upregulation of antioxidant enzymes found in vulnerable neurons in Alzheimer's disease. Not surprisingly, stress-activated protein kinase pathways, which are activated by oxidative stress, are extensively activated during Alzheimer's disease. In this review, we present the evidence of oxidative stress and compensatory responses that occur in Alzheimer's disease with a particular focus on the roles and mechanism of activation of stress-activated protein kinase pathways.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17522439     DOI: 10.3233/jad-2007-11202

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  34 in total

1.  Loss of the m-AAA protease subunit AFG₃L₂ causes mitochondrial transport defects and tau hyperphosphorylation.

Authors:  Arun Kumar Kondadi; Shuaiyu Wang; Sara Montagner; Nikolay Kladt; Anne Korwitz; Paola Martinelli; David Herholz; Michael J Baker; Astrid C Schauss; Thomas Langer; Elena I Rugarli
Journal:  EMBO J       Date:  2014-03-28       Impact factor: 11.598

Review 2.  Novel therapeutics for Alzheimer's disease: an update.

Authors:  David J Bonda; Hyun-Pil Lee; Hyoung-gon Lee; Avi L Friedlich; George Perry; Xiongwei Zhu; Mark A Smith
Journal:  Curr Opin Drug Discov Devel       Date:  2010-03

Review 3.  Alzheimer's disease pathologic cascades: who comes first, what drives what.

Authors:  Russell H Swerdlow
Journal:  Neurotox Res       Date:  2011-09-13       Impact factor: 3.911

Review 4.  Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies.

Authors:  Michael W Marlatt; Paul J Lucassen; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

5.  Simultaneous analysis of reactive oxygen species and reduced glutathione content in living cells by polychromatic flow cytometry.

Authors:  Andrea Cossarizza; Roberta Ferraresi; Leonarda Troiano; Erika Roat; Lara Gibellini; Linda Bertoncelli; Milena Nasi; Marcello Pinti
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

6.  Association of selenoprotein p with Alzheimer's pathology in human cortex.

Authors:  Frederick P Bellinger; Qing-Ping He; Miyoko T Bellinger; Yanling Lin; Arjun V Raman; Lon R White; Marla J Berry
Journal:  J Alzheimers Dis       Date:  2008-11       Impact factor: 4.472

7.  Direct and indirect roles of cyclin-dependent kinase 5 as an upstream regulator in the c-Jun NH2-terminal kinase cascade: relevance to neurotoxic insults in Alzheimer's disease.

Authors:  Kai-Hui Sun; Hyoung-gon Lee; Mark A Smith; Kavita Shah
Journal:  Mol Biol Cell       Date:  2009-09-23       Impact factor: 4.138

Review 8.  Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention.

Authors:  Diana F Silva; J Eva Selfridge; Jianghua Lu; Lezi E; Sandra M Cardoso; Russell H Swerdlow
Journal:  Adv Pharmacol       Date:  2012

9.  Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases.

Authors:  Yang Yu; Xiaoqin Run; Zhihou Liang; Yi Li; Fei Liu; Ying Liu; Khalid Iqbal; Inge Grundke-Iqbal; Cheng-Xin Gong
Journal:  J Neurochem       Date:  2009-01-13       Impact factor: 5.372

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.